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Background: Progesterone is essential for the proliferation and differentiation of mammary gland epithelium.
Studies of breast cancer cells have demonstrated a biphasic progesterone response consisting of an initial
proliferative burst followed by sustained growth arrest. However, the transcriptional factors acting with the
progesterone receptor (PR) to mediate the effects of progesterone on mammary cell growth and differentiation
remain to be determined. Recently, it was demonstrated that signal transducer and activator of transcription 6
(Stat6) is a cell growth suppressor. Similar to progesterone-bound PR, Stat6 acts by inducing the expression of the
G1 cyclin-dependent kinase inhibitors p21 and p27. The possible interaction between Stat6 and progesterone
pathways in mammary cells was therefore investigated in the present study.
Methods: ChIP and luciferase were assayed to determine whether Stat6 induces p21 and p27 expression by
recruitment at the proximal Sp1-binding sites of the gene promoters. Immunoprecipitation and Western blotting
were performed to investigate the interaction between Stat6 and PR-B. The cellular DNA content and cell cycle
distribution in breast cancer cells were analyzed by FACS.
Results: We found that Stat6 interacts with progesterone-activated PR in T47D cells. Stat6 synergizes with
progesterone-bound PR to transactivate the p21 and p27 gene promoters at the proximal Sp1-binding sites. Moreover,
Stat6 overexpression and knockdown, respectively, increased or prevented the induction of p21 and p27 gene expression
by progesterone. Stat6 knockdown also abolished the inhibitory effects of progesterone on pRB phosphorylation, G1/S cell
cycle progression, and cell proliferation. In addition, knockdown of Stat6 expression prevented the induction of breast cell
differentiation markers, previously identified as progesterone target genes. Finally, Stat6 gene expression levels increased
following progesterone treatment, indicating a positive auto-regulatory loop between PR and Stat6.
Conclusions: Taken together, these data identify Stat6 as a coactivator of PR mediating the growth-inhibitory
and differentiation effects of progesterone on breast cancer cells.
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The steroid hormones estrogen and progesterone play
key roles in the growth of the mammary gland [1].
Estrogens appear to be the main drivers of proliferation
of the mammary gland epithelium, whereas progesterone
is required for its terminal growth and differentiation
[2]. The induction of mammary epithelial development
during pregnancy is mediated by a rise in progesterone
levels [3,4]. Progesterone exerts its physiological effects
mainly via interaction with specific intracellular proges-
terone receptors (PRs), PR-A and PR-B, which are prod-
ucts of a single gene and are members of the nuclear
receptor (NR) family [5]. Studies on mice in which the
expression of both PRs was ablated have demonstrated
that progesterone is necessary for ductal branching and
the lobulo-alveolar development of the mammary gland
[6]. More recently, selective ablation of each receptor
isoform has indicated that PR-B is specifically required
for the progesterone-dependent development of the
mammary gland during pregnancy [7].
In relation to the function of progesterone in breast
development, both growth-stimulatory and -inhibitory
effects on breast epithelium cells and cancer develop-
ment have been reported in animal tumor models
[8-10]. Moreover, in vitro studies using the PR-positive
mammary carcinoma T47D cell line as a model have
demonstrated a biphasic cellular response to either pro-
gesterone or its derivatives (R5020 or ORG2058), with
an immediate proliferative burst followed by a sustained
growth arrest [11-13]. As with many hormones and
growth factors, the regulation of retinoblastoma gene
product (pRB) phosphorylation, a critical checkpoint in
the G1/S transition, plays a major role in the control of
proliferation by progesterone [14-16]. The initial pRB
phosphorylation provoked by progesterone is catalyzed
by constitutively-expressed cyclin-dependent kinases
(CDKs), which are activated through interaction with
specific cyclins induced by progesterone [14,15,17]. The
ensuing growth arrest is associated, at least in part, with
the transitory induction of cyclin-dependent kinase in-
hibitors (CDKIs) p21 and p18, followed by sustained in-
duction of p27 [18-20]. Associations of these CDKIs
with the different G1 CDK complexes led to inhibition
of their activity and a decrease in pRB phosphorylation,
resulting in cell cycle arrest in late G1 phase. It is known
that progesterone induces the expression of both p21
and p27 through a transcriptional mechanism that in-
volves interaction between progesterone-bound PR, the
general coactivator CBP/p300, and the transcription fac-
tor Sp1 at proximal Sp1-binding sites [19,21]. However,
since PR is expressed during both phases of the proges-
terone response [11-14], unidentified PR target genes
and/or cofactors of PR are likely to be involved with it in
the delayed growth-inhibitory effects of progesterone.Signal transducer and activator of transcription 6
(Stat6) was isolated as a novel factor implicated in the
regulation of various cytokine genes [22,23]. Recently,
we identified a new function for Stat6 as a growth sup-
pressor protein in CHO and mammary cancer cells (in
submission). As with PR, the antiproliferative activity of
Stat6 involves its interaction with Sp1 to activate the
p21 and p27 promoters, resulting in the inhibition of G1
CDK-mediated phosphorylation of pRB and histone H1.
In view of the ability of Stat6 to function as a nuclear re-
ceptor coactivator, in this study we tested whether Stat6
interacts with PR and influences the progesterone-
dependent regulation of mammary cancer cell growth.
Using the T47D cell line as a model, we show that Stat6
is indeed a coactivator of PR at the p21 and p27 gene
promoters. Furthermore, we show that Stat6 gene ex-
pression itself is steadily induced by progesterone, which
is necessary for the long-term growth-inhibitory and dif-
ferentiating effects of the hormone. Thus, Stat6 is likely
to mediate a positive feedback loop in the progesterone
response that is crucial for the delayed and sustained ac-
tion of progesterone on breast cancer cells.
Methods
Plasmids
The Stat6 expression vector subcloned in pCMV4-flag
was constructed as previously described. The 2.4-kilo-
base pair genomic fragment containing the transcription
start site of P21 was subcloned into the HindII site of
the luciferase reporter vector, pGL3-Basic (Promega), to
generate P21Luc. The p27 promoter reporter constructs
were a gift from Dr. Toshiyuki Sakai (Kyoto Prefectural
University of Medicine) [24].
Cell culture assays
Human T47D ductal carcinoma cells, a model com-
monly used to study progesterone signaling in breast
cancer cells, were obtained from the American Type
Culture Collection (Rockville, MD) and were cultured as
a monolayer as previously described [25]. In all assays,
the cells were first synchronized in G0/G1 phase by a
double thymidine block as previously described [26].
Progesterone (30 nM) or ethanol (vehicle) was added
daily when the cells resumed proliferation by reincuba-
tion in routine growth medium (corresponding to time
zero of the experiments). Each experiment was repeated
at least three times, and the results are presented as
means ± standard deviations (SD) of a representative
experiment carried out in triplicate. Cellular DNA con-
tent and flow cytometry profiles were determined, re-
spectively, by the staining of nuclear DNA using the
fluorochrome 3,5-diaminobenzoic acid (free acid) and
propidium iodide as described previously [27]. Transient
transfections were performed with Lipo2000 (Invitrogen,
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immunoprecipitation assays were performed as described
elsewhere [28] using 40 μg of anti-Stat6 (Abcam), anti-
Progesterone Receptor, (anti-PR, specific for the β-form of
PR) (Abcam), and anti-p300 (Santa Cruz) and anti-Sp1
(Santa Cruz) antibodies for the immunoprecipitation of cell
lysates. Briefly, T47D cells were subjected to chromatin im-
munoprecipitation (ChIP) with the ChIP Assay kit (Upstate
Cell Signaling Solutions). Briefly, cross-linking of proteins
with DNA was done with 4% formaldehyde at 37°C for 15
minutes and quenched with glycine. Cell lysates were soni-
cated (Branson Sonifier) to shear the DNA to 400- to
1,000-bp length fragments. Chromatin samples were then
precleared with a salmon sperm DNA/protein A agarose
50% slurry for 30 minutes at 4°C and immunoprecipitated
overnight in the absence of antibody or with antibodies for
flag, Stat6, PR, Sp-1, and p300. The PCR products were
separated on a 2% agarose gel, stained with ethidium brom-
ide, and visualized under UV light.
Immunostaining
T47D cells, subconfluently grown on glass coverslips,
were transfected with small interfering RNA (siRNA),
treated with progesterone or ethanol (vehicle) for 48 h,
and then fixed and permeabilized with 4% formaldehyde
and 0.5% Triton X-100 in PBS for 10 minutes. For fluor-
escent immunocytochemistry, the cells were first perme-
abilized by boiling in 10 mM citrate buffer. The rabbit
polyclonal Stat6 antibody (1:50; Abcam) was then de-
tected with an FITC-conjugated goat anti-rabbit im-
munoglobulin G (1:500; Sigma). Following three washes
with PBS, the cells were incubated with an actin-specific
marker, phalloidin (Sigma). After three washes, the cov-
erslips and their attached cells were mounted on glass
microscope slides using mounting medium with DAPI
(Molecular Probes). To detect lipid, cells were stained
with Oil Red O and counterstained with hematoxylin.
Specimens were visualized and photographed using a
Leica TCS-SP2 confocal microscope (for fluorescent
immunocytochemistry) or a Leica DC480 color video
camera (for Oil Red O staining). Oil Red O staining
intensity was quantified as described in [29]. Results rep-
resent the means ± SD of values from a single experi-
ment (nΧ6fields/point) repeated three times with similar
results.
Reverse transcription and quantitative PCR
Transcript levels in extracted total RNA were assessed
by quantitative reverse transcription-PCR (RT-PCR)
using the oligonucleotide primers specific for human
Stat6, p21, and p27 as described previously (24). In
addition, the following primer pairs were used: desmo-
plakin, 5′-TGATAAACTCAGACAGCGCC-3′ and 5′-
CATCAAACACCAGCTTGGAG-3′; Na/K-ATPase-α1,5′-CTGGCTTGAGGCTGTCATCTTCCTC-3′ and 5′-TT
CCTTGCCATGCGTTTGGC-3′; fatty acid synthase
(FAS), 5′-ATCGTGGACGGAGGCATCAACC-3′ and 5′-
TTGGCCATCATCGCTCGCTG-3′; non-tissue-specific al-
kaline phosphatase (ALP), 5′-TCACTCTCCGAGATGGT
GGTGGTGG-3′ and 5′-TTCCTTCATGGTGCCCGTG
G-3′. Because of their stability during cell cycle progres-
sion, GADPH levels were simultaneously quantified for
normalization. Each figure indicates mRNA levels as
means ± SD (n = 3).
Knockdown of Stat6 expression
Stat6 expression was knocked-down using siRNA as de-
scribed elsewhere [30]. Briefly, the oligonucleotides used
to generate three Stat6 siRNAs targeting three distinct
regions of Stat6 cDNA (siRNA-1: 5′-GGGAGAAGAU
GUGUGAAACUCUGAA-3′, siRNA-2: 5′-GAAUCCGG
GAUCUUGCUCAGCUCAA-3′, and siRNA-3:5′-CAG
UUCCGCCACUUGCCAAdTdT-3′) were synthesized by
Invitrogen. The nonsilencing siRNA oligonucleotide, which
does not target any known mammalian gene and is used as
a negative control, was from Ambion. siRNA duplexes
(500 ng) were transfected at 0 and 3 days using Lipo2000
(Invitrogen, Carlsbad, USA). Down-regulation of the target
gene (Stat6) by specific siRNA but not by negative con-
trols was confirmed by Western blotting (Additional
file 1: Figure S1). Representative experiments have
been performed with Stat6 siRNA-3.
Protein assays
Immunoprecipitation assays were performed as previ-
ously described [31]. Cells were washed twice with PBS,
collected and homogenized with RIPA buffer. After cell
debris was removed by centrifugation, extracts were ali-
quoted and either used immediately or stored at −80°C.
Whole-cell lysates in lysis buffer were cleared with
1.0 μg nonimmune rabbit IgG (Santa Cruz) together
with 30 μl of protein A-Sepharose beads (Pierce). After
centrifugation, the lysates were immunoprecipitated for
1 h at 4°C with 1 μg of the anti-Stat6 antibody or nonim-
mune rabbit IgG and then incubated overnight at 4°C
with protein A-Sepharose. The immunoprecipitates were
washed three times with lysis buffer and once with PBS
and then resuspended in electrophoresis sample buffer.
Samples of immunoprecipitated or total proteins (30 μg)
were analyzed by Western blotting using the anti-ppRB-
Ser807/811 antibody (Cell Signaling Technology) against a
pRB peptide phosphorylated on the Ser807/811 residue,
which is phosphorylated by both CDK2 and CDK4/6 ki-
nases [32], or the anti-pRB against underphosphorylated
pRB (BD Biosciences-Pharmingen), the anti-PR antibody
(abcam), anti-p21(abcam), anti-p27(abcam), and anti-
GADPH (as control antibody). The blots represent typical
results from at least three independent experiments.
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Statistical analyses were performed using the nonpara-
metric Mann–Whitney test.
Results
Stat6 enhances the progesterone response of the p21
and p27 gene promoters
Previously, we demonstrated that Stat6 induced the p21
and p27 genes by interacting with Sp1 through the prox-
imal Sp1-binding elements (comprising the Sp1-3 and
Sp1-4 sites for p21 and the Sp1-1 and Sp1-2 sites for
p27). Coincidentally, progesterone-bound PR has been
shown to activate the p21 and p27 genes by interacting
with Sp1 through the same proximal Sp1-binding ele-
ments [19,21]. Therefore, it was hypothesized that Stat6
and PR could interact functionally at these proximal Sp1Figure 1 Stat6 enhances p21 and p27 promoter activities induced by
reporter constructs containing the indicated p21 (A) or p27 (B) promoter f
progesterone (30 nM) or vehicle (ethanol) for 24 h and then harvested for
SD) over luciferase activity levels in control (−) p21Luc or p27Luc, arbitrarily
indicate the mutated Sp1-binding sites. For each promoter construct, colum
from each other.response elements to activate transcription of both pro-
moters. To test this, wild type p21 or p27 promoter
reporter constructs (denoted p21Luc and p27Luc, re-
spectively) were cotransfected with the Stat6 expression
plasmid in PR-positive breast carcinoma T47D cells
[33,34], and the cells were treated with progesterone or
left untreated (Figure 1). Confirming the results of previ-
ous studies [19,21], Stat6 or progesterone treatment
alone stimulated both p21 and p27 gene promoter activ-
ities. Interestingly, a synergistic effect of Stat6 and pro-
gesterone was observed on both CDKI promoters. To
assess the roles of the Sp1 sites in this response further,
the p21 and p27 reporter constructs mutated at each
Sp1 site were transiently cotransfected with Stat6 in
cells either untreated or incubated with progesterone
(Figure 1). As previously reported, the mutation of theprogesterone. T47D cells were transiently cotransfected with the
ragments. Twelve hours after transfection, cells were incubated with
the luciferase activity assay. Results are expressed as increase (mean ±
set as 1. The arrows represent the transcription start sites; the crosses
ns followed by different symbols are statistically significantly different
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and abolished the responses of the p21 or p27 promoters
to Stat6 or progesterone alone [19,21,35]. Moreover, mu-
tation of the Sp1-4 or the Sp1-2 site reduced the
progesterone-dependent transactivation of the p21 or
p27 promoter, respectively. However, mutation of each
of these sites prevented the synergistic effects of Stat6
and progesterone on both promoters. These results indi-
cate that Stat6 cooperates with the progesterone path-
way to transactivate the proximal Sp1 response elements
of the p21 and p27 gene promoters.
Stat6 is recruited by progesterone-activated PR at the
proximal Sp1-binding sites of the p21 and p27 gene
promoters
To investigate the in-cell occupancy of these Sp1-binding
sites by Stat6 and the influence of progesterone on this,
chromatin immunoprecipitation assays were performed on
DNA isolated from T47D cells either treated with proges-
terone or untreated (Figure 2A). Consistent with our previ-
ous findings in CHO cells (data not shown), Stat6 was
found by immunoprecipitation to be associated with the
proximal Sp1-binding elements of the p21 and p27 genes.
Moreover, this association was greater in the progesterone-
treated than in the parallel control cells. Statistical analysis
of quantifications of the p21 and p27 promoter sequences
bound by Stat6 in ChIP assays are presented in Additional
file 2: Figure S2.
Previous reports have indicated that the CBP/p300
protein functions as a coactivator of PR [21,36,37] and
cooperates with PR at the proximal Sp1-binding sites of
the p21 and p27 gene promoters to increase their activ-
ities [19,21]. Consistent with these data, PR, Stat6, and
Sp1 were found to be present together with CBP/p300 at
the proximal Sp1 elements of the p21 and p27 pro-
moters in progesterone-treated T47D cells (Figure 2B).
As a control of specificity, amplification using primers
covering regions <1 kb upstream of these sites or oligo-
nucleotides specific for the β-actin gene resulted in non-
relevant background products.
In order to determine whether PR, Stat6 and p300
interact with each other and how they are presented in
the complex, we conducted systematic immunoprecipi-
tation assays and the results are presented in Additional
file 3: Figure S3. Extracts from control or progestrone-
treated cells were immunoprecipitated to determine
whether Stat6 binds to PR or p300. As demonstrated in
Additional file 3: Figure S3, progestrone treatment
increased the level of Stat6 in the complexes immuno-
precipitated with anti-PR but not in complexes immu-
noprecipitated with anti-p300. Reprobing the filters
with anti-PR and anti-p300 antibodies confirmed that
the immunoprecipitates from control and progestrone-
treated cells contained the same levels of PR and p300.Therefore, progestrone appears to cause a selective
increase in Stat6 binding to PR. The IP and WB assay
results confirmed that Stat6 binds to PR. Furthermore,
by luciferase assays, Stat6 and PR cooperated to induce
P21 and P27 transcriptional activities.
The putative interaction between Stat6 and progesterone-
activated PR was then examined. To this end, we first
determined in co-immunoprecipitation assays whether
endogenous Stat6 and PR interact in T47D cells either un-
treated or treated for 12 h with progesterone and the partial
PR antagonist RU486 (Figure 3A). Low levels of endogen-
ous PR were found in the complex immunoprecipitated
with the anti-Stat6 antibody in untreated T47D cells. How-
ever, the amount of PR co-immunoprecipitated with Stat6
was drastically increased in cells treated with progesterone
alone. This effect was attenuated by co-treatment with
RU486 (Additional file 4: Figure S4). From Figure 3A we
detected that compared with cells treated with progester-
one alone the PR-B protein level was highly enriched by co-
treatment with both RU486 and progestrone in western
blotting assays, whereas the PR-B protein immunoprecipi-
tated by anti-Stat6 antibody was drastically decreased.
RU486 is a well-characterized PR antagonist that binds to
the receptor and blocks its gene regulatory function. For
RU-486 competitively binds better than progesterone does
to the receptor, progesterone is then not able to bind to its
own receptor. Although RU486 blocks PR transcriptional
activity by favoring corepressors recruitment, it was found
that PR turnover was highly reduced after RU486 treat-
ment [10-13]. Like progesterone, RU486 stimulates similar
early cascade of events, including chaperone dissociation,
dimerization, and posttranslational modifications, such as
sumoylation and phosphorylation, which might give ex-
planation of the inconsistency of Stat6 protein levels be-
tween western blotting and immunoprecipitaition assays.
To assess further whether Stat6 interacts in vivo with
PR, co-immunoprecipitation assays were performed on
cells transfected with the flag–Stat6 vector (Figure 3B).
The results indicated that Stat6 interacts physically with
PR and that this interaction is enhanced in a dose-
dependent manner by progesterone (Figure 3B, top left
panel). Consistent with Figure 3A, the binding observed
between Stat6 and progesterone-activated PR diminished
in the presence of RU486 (Figure 3B, top right panel).
Indeed, consistent results came from other PR-positive
cell lines including MCF-7 (Additional file 5: Figure S5).
Besides, the results of immunoprecipitation assays sug-
gested that Stat6 might act as a downstream target of
PR. In order to determine whether there might be PR-
responsive elements in the Stat6 promoter or other
regulatory elements we have conducted luciferase assays
on the cells cotransfected with vectors carrying PRB
cDNA and Stat6 promoter sequences and none signifi-
cant changes have been detect. Consistently, previous
Figure 2 Progesterone enhances Stat6 recruitment at multiprotein complexes formed with PR and CBP/p300 at proximal Sp1 elements
of the p21 and p27 promoters. Chromatin was prepared from T47D cells incubated with progesterone (30nM) or ethanol (vehicle) (A) or
with progesterone (30 nM) alone (B) for 4 h before lysis. Immunoprecipitations were then performed using antibodies as indicated (top).
Controls included PCRs done without DNA (H2O) or with nonprecipitated genomic DNA (input) or immunoprecipitation assays performed
without antibody (no Ab) or with an irrelevant antibody (anti-flag). The extracted DNA was amplified using the primer pairs covering either the
progesterone-responsive Sp1-binding region of the p21 gene promoter (upper panel), a distal region of the p21 gene located ~1 kb from this
element, the 544/533 progesterone-responsive Sp1-binding region of the p27 gene promoter, a distal region of the p27 gene located ~1 kb from
this element, or a β-actin gene region (lower panel).
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T-47D breast cancer cells[9].
We previously demonstrated that Stat6 carries the
transactivation domain (TAD), containing one putative
LXXLL motif at amino acids 802 to 806, which are
nuclear receptor interaction domains in numeroustranscriptional co-regulatory proteins [38]. Interest-
ingly, mutation of the LXXLL motif drastically reduced
the binding of Stat6 to PR. This indicates the import-
ance of the LXXLL motif in the in vivo interaction be-
tween Stat6 and PR (Figure 3B, lower panel). Besides,
to further investigate the function of LXXLL motif in
Figure 3 Stat6 interacts directly with progesterone-bound PR via its LTKLL in the TAD domain. A. Coimmunoprecipitation assays. T47D
cells were treated with progesterone (30 nM) and RU486 (10 nM) for 12 h, or untreated. Total protein extracts (50 μg) were then subjected to
Western blotting using a PR antibody either after immunoprecipitation with anti-Stat6 or nonimmune rabbit IgG (negative control) antibodies
(upper panel) or directly for control of the in-cell PR levels (lower panel). B. as in A, coimmunoprecipitation assays were conducted on cells with
the indicated treatment. C, flag–Stat6, either wild type or mutated in the LTKLL (flag-Stat6m) motif, was assayed for interaction with PR as
described above in the presence of progesterone (10 nM).
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p27 promoter we conducted luciferase assays and RT-
PCR assays using a LXXLL-mutant of Stat6, flag-Stat6-
m (Additional file 6: Figure S6). Consistently we got
that Stat6 suppresses p21 and p27 transcriptional ac-
tivity, which was abated by flag-Stat6-m transfection.
Taken together, these results suggest that Stat6 is re-
cruited by progesterone-activated PR through its LXXLL
motif in TAD in the regulatory complexes formed with
Sp1 at the proximal Sp1-binding sites of the p21 and
p27 gene promoters.
Stat6 is required for the progesterone-induced increase
of p21 and p27 expression and inhibition of G1/S cell
cycle progression
The next question we addressed was whether Stat6 is re-
quired to induce p21 and p27 expression as well as in
the regulation of cell proliferation by progesterone.
First, the expression of both genes in response to pro-
gesterone was assessed in T47D cells in which Stat6 ex-
pression was silenced using a siRNA strategy (Figure 4).As the results demonstrate, the decrease of Stat6 expres-
sion triggered a significant down-regulation of both p21
and p27 mRNA (Figure 4A) and protein (Figure 4B)
levels. Moreover, in good agreement with previous ob-
servations [19,39], progesterone treatment resulted in an
early and transient up-regulation of p21, followed by a
delayed and sustained up-regulation of p27. Strikingly,
this progesterone-dependent modulation of p21 and p27
gene expression was completely abolished upon siRNA-
mediated specific silencing of Stat6.
Next, the influence of Stat6 silencing on the growth
inhibitory effects of progesterone was tested. Consistent
with previous reports, cell growth in the control was
inhibited by progesterone after 4 and 6 days of treatment
as a consequence of p21 and p27 up-regulation [19,39].
However, siRNA silencing of Stat6 completely prevented
the growth-inhibitory effects of progesterone (Figure 5A).
To assess the specificity of this effect, the role of Stat6 in
the response to rosiglitazone, a ligand of peroxisome
proliferator-activated receptor γ (PPARγ), which has pre-
viously been reported to inhibit mammary cancer cell
Figure 4 Stat6 mediates the induction of p21 and p27 gene expression by progesterone. T47D cells, treated with or without progesterone
(30nM) and transfected with control or Stat6 siRNAs (500 ng), were harvested at the indicated times for RNA (A) and protein (B) extraction.
(A) Quantitative RT-PCR analyses. mRNA levels are expressed relative to levels in vehicle-treated control siRNA-transfected cells harvested at 24 h,
arbitrarily set as 1. *P ≤ 0.05 versus control. (B) Western blotting of p21 and p27 with GADPH as control.
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gesterone, silencing of Stat6 did not alleviate the
growth-inhibitory effects of rosiglitazone on T47Dcells (Figure 5B). This therefore indicates that Stat6
specifically mediates the inhibition of breast cancer
cell proliferation by PR.
Figure 5 siRNA silencing of Stat6 abolishes inhibition of T47D cell proliferation by progesterone but not by rosiglitazone. T47D cells,
treated with or without progesterone (A) (30 nM) or rosiglitazone (B) (0.5 μM) and transfected with control or Stat6 siRNAs (500 ng), were
harvested at 1, 2, or 3 days for measurement of DNA content. ns, not significant; *, P ≤ 0.05; **, P ≤0.01; ***, P ≤ 0.001 versus control.
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pRB phosphorylation status were analyzed (Figure 6). As
previously reported [42,43], progesterone induced an ini-
tial acceleration of cell cycle progression (Figure 6A, left
panel; performed after 12 h of progesterone treatment),
followed by inhibition of the G1/S transition (Figure 6A,
right panel; performed after 24 h of progesterone treat-
ment), which was associated with an inhibition of pRB
phosphorylation (Figure 6B; performed 24 h after pro-
gesterone treatment). Interestingly, siRNA-induced Stat6
silencing did not affect the early cell mitogenic response
to progesterone. In contrast, Stat6 knockdown prevented
the subsequent decrease in the percentage of cells in S
phase and in the regulation of phosphorylated and dephos-
phorylated pRB levels (Figure 6A, right panel, and B).
Collectively, these data indicate a specific role for Stat6 as
a coactivator of PR in the regulation of the progesterone-
induced G1-phase cell cycle arrest of breast cancer cells.
Stat6 mediates the differentiation-enhancing activities of
progesterone in breast cancer cells
Recent in vitro studies have associated the ability of pro-
gesterone and its derivatives to control mammary cancer
cell proliferation negatively by inducing a cell differenti-
ation program [39,44], which leads to the acquisition of
a secretory phenotype [45,46]. Therefore, we tested
whether siRNA silencing of Stat6 also influences the ef-
fects of progesterone on T47D cell differentiation. To
this end, the expression levels of a panel of previously
identified markers of early and terminal differentiation
in breast cancer cells [47,48] were measured (Figure 7A
and B). As reported, progesterone induced the early
gene expression of desmoplakin and Na+/K+-ATPase α1,
which are markers for epithelial differentiation andglandular development, respectively [47,48] (Figure 7A).
Moreover, consistent with previous data [49-51], proges-
terone increased the expression of FAS (fatty acid syn-
thetase) and ALP (alkaline phosphatase), which are
markers of differentiation correlating with lipid storage
in breast cancer cells (Figure 7B). Interestingly, the in-
duction of each of these mRNA levels was abolished by
Stat6 knockdown (Figure 7A and B). Concurring with
these RNA data, progesterone treatment induced an ac-
cumulation of lipid droplets as visualized by Oil Red O
staining, and this effect was significantly decreased by
~87% in Stat6-deficient cells (Figure 7C).
Therefore, the induction of a differentiated secretory
phenotype of breast cancer cells by progesterone re-
quires the expression of Stat6.
Stat6 gene expression is induced by progesterone
Since progesterone exerts biphasic effects on mammary
cancer cell proliferation despite the continuous presence
of transcriptionally competent PR, it has been proposed
that the long-term growth arrest provoked by progester-
one requires the induction of additional factors [42,43].
To determine whether Stat6 expression is regulated by
progesterone, Stat6 mRNA levels were measured by
quantitative RT-PCR analysis in T47D cells following
progesterone treatment (Figure 8). Interestingly, treat-
ment with progesterone provoked a long-lasting increase
in Stat6 mRNA levels, which was already obvious within
12 h of treatment (Figure 8A, left panel). The induction
of Stat6 mRNA expression by progesterone was inhib-
ited by actinomycin D (an inhibitor of RNA polymerase
II) but not by cycloheximide (a transcriptional inhibitor
of protein synthesis) (Figure 8A, right panel), indicating
that progesterone-bound PR could directly induce Stat6
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Stat6 protein levels increased in progesterone-treated T47D
cells, as shown by Confocal Laser Scanning Microscopy
after 24 h of progesterone treatment (Figure 8B). Together,
these results indicate that Stat6 is progesterone-responsive
gene acting with PR in a positive feedback loop that
inhibits mammary cell proliferation and stimulates
differentiation.
Discussion
It has been proposed that the delayed growth arrest pro-
voked by sustained progesterone treatment requires the
presence and/or activation of other transcription factors
and/or co-regulators acting with PR [46,52]. Both Stat6
and progesterone have previously been shown to act at
the G1/S transition checkpoint through similar mecha-
nisms, i.e., transcriptional induction of the p21 and p27
CDKI gene promoters via their proximal Sp1-binding
sites [19,21]. Knockdown of p21 and p27 expression using
a siRNA approach prevented the growth-inhibitory re-
sponse to either progesterone or Stat6 ([19,21] (Additional
file 7: Figure S7), highlighting their requirements for both
inhibitory pathways. Therefore, in the present study, we
also investigated possible cross-talk between PR and Stat6Figure 6 Stat6 is required for the inhibition of G1/S cell cycle progres
control or Stat6 siRNAs (500 ng) and treated with or without progesterone
distribution (A) or Western blotting using either an antibody raised against
specifically the underphosphorylated form of pRB (B). Representative Weste
on the Ser807/811 residue; pRB, hypophosphorylated pRB. The MDA-MB-46
pRB staining.in the control of these cell cycle-regulating genes in the
Stat6- and PR-expressing mammary carcinoma T47D cell
line. Our results indicate that Stat6 is rapidly recruited fol-
lowing progesterone treatment to the multiprotein complex
formed with PR and CBP/p300 at the proximal Sp1-
binding elements of the p21 and p27 gene promoters.
Moreover, Stat6 and progesterone synergize to transactivate
the p21 and p27 gene promoters through these proximal
Sp1-binding sites. Co-immunoprecipitation on intact cells
and flag –Stat6 vector transfected cells further revealed a
physical interaction between PR and Stat6 that was en-
hanced by progesterone and mediated by the two LXXLL
NR-boxes of Stat6. These observations thus identify a novel
function for Stat6 as a coactivator of PR implicated in the
progesterone-dependent regulation of the p21 and p27
genes.
Basal Stat6 levels could be sufficient to initiate the
growth-inhibitory progesterone response via a direct
transcriptional effect on the p21 and p27 gene pro-
moters. Indeed, the induction of p21 and p27 observed
after 24 h progesterone treatment was inhibited by the
RNA polymerase II inhibitor actinomycin D but was not af-
fected by the protein synthesis inhibitor cycloheximide
(Additional file 8: Figure S8). However, it was noteworthysion by progesterone. Synchronized T47D cells, transfected with
, were harvested after 12 h or 24 h to determine cell cycle phase
pRB phosphorylated at Ser807/811 or an antibody recognizing
rn blotting results are shown in B. pRB-Ser807-811, pRB phosphorylated
8 cell line, deficient in pRB expression, was used as a negative control of
Figure 7 Stat6 silencing prevents the induction of differentiation by progesterone. Synchronized T47D cells transfected with control or
Stat6 or siRNA (500 ng) and treated with progesterone (30 nM) or vehicle were harvested after 12 h (A) or 4 days (B and C) for quantitative
RT-PCR analyses (A and B) and Oil Red O staining for lipid droplets (C). In panels A and B, mRNA levels are expressed relative to vehicle-incubated
control siRNA-transfected cells, which were arbitrarily set as 1. NS, not significant; *, P ≤ 0.05; **, P ≤0.01; ***, P ≤ 0.001 versus control. C. Lipid
detection. Left panel: representative Oil Red O-stained cellular sections. Right panel: quantification of the lipid staining intensity.
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steady induction of Stat6 gene expression itself. Although a
positive control by progesterone of the expression of PRcoactivators such as SRC-1 and CBP/p300 has been
observed in normal human endometrium [53], such
molecular pathways have not, to our knowledge, yet
Figure 8 Stat6 gene expression is induced by progesterone. Synchronized T47D cells were treated with or without progesterone (30nM) for the
indicated times (A, left panel) or for 24 h (A, right panel, and B). A. Quantitative PCR analysis. mRNA levels are expressed relative to levels in vehicle-treated
control cells harvested at 6 h, arbitrarily set as 1. Right panel. Cycloheximide (5 μg/ml) or actinomycin D (10 μg/ml) was added to the medium 2 h before
the addition of progesterone or ethanol (vehicle). h, hour; d, day; NS, not significant; *, P ≤ 0.05; **, P ≤0.01 versus control. B. Modulation of progesterone on
Stat6 was detected in T47D cells after 24 h progesterone treatment using Confocal Laser Scanning Microscope. Coverslips seeded with synchronized T47D
cells treated with or without progesterone (30nM) and vehicle were triple-stained with Stat6 antibody and one secondary antibody conjugated with FITC
to permit detection of Stat6 (a), phalloidin to permit detection of actin (b), and DAPI, a DNA-binding dye, to counterstain the DNA (c). In T47D cells, Stat6
accumulated in nuclear domains that colocalized with dense regions of DAPI staining (d).
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knockdown experiments revealed that Stat6 expression
is necessary for the consecutive progesterone-induced
transitory p21 and long-lasting p27 increases and the
consequent inhibitory effects on G1/S cell cycle pro-
gression. These data indicate that Stat6, as both a PR
cofactor and a target gene, mediates a positive feed-
back loop participating in the growth-inhibitory re-
sponse to progesterone.
Stat6 deficiency did not affect the previously-reported
rosiglitazone-induced inhibition of breast cancer cell
growth [40,41]. Interestingly, Stat6 siRNA did not affect
the transcriptional up-regulation by progesterone of ei-
ther metallothionein IIA or pepsinogen C, which are
genes not directly related to cell cycle control and are
regulated by progesterone via a canonical PR-responsive
element (5, 63) (Additional file 9: Figure S9). Thus, spe-
cific interactions between PR, Stat6, and other proteins
included in the multiprotein complexes formed at prox-
imal Sp1-binding elements of the cell cycle regulatory
p21 and p27 genes appear to exist and underlie the
growth-inhibitory response to progesterone. Importantly,
lowering the Sp1 levels by ~70% using a siRNA ap-
proach resulted in a significant decrease of p21 and p27mRNA levels in both the absence and presence of pro-
gesterone (Additional file 10: Figure S10). This indicates
that Sp1 is required for basal and progesterone-
stimulated p21 and p27 promoter activities. However, as
shown for the transactivation of the p21 gene by PPARγ
[54,55], it is obvious that a contribution of Sp3 and/or
Sp4 protein to the regulation of the p21 and/or p27 pro-
moters by Stat6 and progesterone cannot be excluded.
Besides, in addition to the LXXLL motif of TAD, the pri-
mary structure of Stat6 contains several other putative
interaction domains with co-regulatory proteins [56,57].
Significantly, Stat6 participates in transcriptional regula-
tion by interacting with CBP/p300 [58,59], which is, to
date, the only known PR coactivator that synergizes with
progesterone-bound PR to transactivate the p21 and p27
promoters [19,21]. Whether additional transcriptional
regulatory factors such as CBP/p300 also interact with
Stat6 to mediate the progesterone response therefore re-
mains to be investigated.
However, it is possible that Stat6 binds to nuclear re-
ceptors or cofactors at Sp1 sites of cell cycle regulatory
genes to regulate their expression in contexts other than
the progesterone response. In fact, the proximal Sp1-
binding regions of the p21 and p27 gene promoters
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stance, the Sp1 sites are involved in the transactivation
of the p21 promoter by transforming growth factor [60]
and BRCA1, which is also a co-repressor for the estro-
gen receptor, the androgen receptor, and the PR [61,62].
The proximal Sp1 sites of the p27 promoter are required
for responses to vitamin D3 [63] and tamoxifen [64].
Furthermore, the Sp1-binding sites have a common im-
portant role in modulating the cell cycle [65,66]. Not-
ably, they also mediate the induction of cyclin D1 by
estrogens [67]. Thus, further studies are warranted in
order to determine whether Stat6 could play a more
general role in the cross-talk among different growth
signaling pathways.
Our present data demonstrate that Stat6 itself acts as
a differentiation factor in breast epithelial cancer cells,
notably in the mediation of progesterone effects. Indeed,
the presence of Stat6 was a prerequisite for the induc-
tion of cell differentiation by progesterone, as well as for
the progesterone-dependent increase in the synthesis of
lipid droplets, which is associated with a differentiated
secretory phenotype in mammary cells [49,50]. It is
tempting to propose that p21 and p27 are involved in
the Stat6-dependent effects on breast cancer cell differ-
entiation. In fact, the induction of p21 and p27 has been
shown to constitute a molecular switch that facilitates
hormone-induced differentiation in numerous cell sys-
tems [20,68]. In breast tissue, high levels of p21 and p27
are found in intermediately differentiated and well-
differentiated ductal carcinoma in situ, respectively [69].
Furthermore, p27 up-regulation is thought to be the mo-
lecular basis for the blockage in the alveolar differenti-
ated state [70]. Thus, the molecular mechanisms
underlying the function of Stat6 in mammary cell differ-
entiation and the putative role of p21 and p27 induction
therein remain to be investigated.
The role of PR activity on breast tumorigenesis has
been a subject of controversy. In epidemiological studies,
progesterone levels during a first pregnancy at an early
age are thought to confer protective effects against fu-
ture breast tumor development [71,72]. However, the
possible deleterious effect of certain progestins used in
hormone replacement therapies (HRTs) after menopause
and as contraceptives to counteract the proliferative ac-
tion of unopposed estrogens on the uterus recently res-
urfaced in the Women’s Health Initiative and the
Million Women studies [73,74]. These studies showed
that a combined estrogen plus progestin regimen as
HRT is associated with a greater risk of breast cancer
than estrogen alone or placebo. In spite of these data,
different reports have also indicated that the effects of
progesterone and its derivatives could depend on several
different factors, including the family history of breast
cancer, the mode of administration, and the dose andtype of progestin [75,76]. The delayed action of proges-
terone derivatives on breast cancer cell growth could
explain their potential differential stimulatory or growth-
inhibitory effects, depending on whether the treatment
is transitory or continuous, respectively [11-14]. Interest-
ingly, siRNA knockdown of Stat6 did not modulate the
influence of progesterone on the initial proliferative
burst, as shown by FACS analysis (Figure 6A, left panel)
or proliferation assays (Additional file 11: Figure S11). In
agreement with this, the induction of expression of the
cyclin D1, D3, A, B1, or E genes, which participate in
cell cycle progression [77,78], was not affected by Stat6
siRNA transfection after 12 h of progesterone treatment
(Additional file 12: Figure S12). These data, indicating a
role for Stat6 specifically in the growth-inhibitory re-
sponse to progesterone, suggest that the effects of each
progestin treatment could also depend on levels of Stat6
expression in breast epithelium and/or of Stat6 recruit-
ment to the PR.
In clinical practice, the expression of PR in breast
tumor biopsies is assessed as a predictive marker for fa-
vorable disease prognosis, with the absence of PR
reflecting a nonfunctional estrogen receptor and resist-
ance to hormone therapy [79,80]. Expression levels of
PR correlate with p27 and differentiation status in large
populations of primary mammary tumors [18,81]. p27
mRNA and protein levels in breast cancer biopsies cor-
relate positively with a favorable outcome in human
breast tumors, whereas a loss of p27 gene expression is
associated with a shorter overall survival [82-84]. How-
ever, there is a subgroup of steroid receptor-positive
tumors with low levels of p27, which indicate poor prog-
nosis and are resistant to antiestrogen therapy [85]. It is
tempting to speculate that altered activity of transcrip-
tional factors, such as Stat6, involved with PR in the
(dys)regulation of the p27 gene promoter, could play a
role in p27 loss and mammary tumor development. It is
noteworthy that Stat6 activities affect apoptosis and gene
expression in breast cancer cells [86]. Moreover, the
human Stat6 gene lies on the chromosome 12q13.3-
q14.1 locus [87]. The recently published Cancer Genome
Atlas (TCGA) data set [88] includes high-resolution in-
formation on DNA copy number, mRNA and microRNA
expression, DNA methylation, single-nucleotide polymor-
phisms, and somatic mutations in cancer. One of the most
common copy-number alterations in breast cancer is amp-
lification at chromosome 12q13.3–14.1, which is also amp-
lified in melanoma and lung cancers [89]. The CDK4
gene has been proposed as the target of this amplification.
CDK4 promotes proliferation by inhibiting the RB1 tumor
suppressor and by sequestering p27Kip1 and p21Cip1,
thereby promoting E2F- and Cdk2-dependent cell cycle
progression [90]. However, CDK4 overexpression
alone does not induce spontaneous tumorigenesis in
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erates with other genetic changes during tumorigenesis
[90]. Analyses of potential correlations between genetic
alterations of Stat6, CDK4 and p27 expression could be de-
cisive in clarifying the role of Stat6 in familial predisposition
to certain cancers and/or failure of hormonal therapy.
Following tamoxifen, the first identified selective estro-
gen receptor modulator, a number of other antiestrogens
have been developed [91]. The notion that selective
nuclear receptor modulators can exhibit cell- and tissue-
specific effects has also been extended to a panel of
other nuclear receptors [92]. Selective progesterone re-
ceptor modulators, such as Asoprinil, are now under in-
vestigation in the treatment of uterine fibroids and
endometriosis [93]. However, to date, they have mostly
been identified by empirical and in vitro studies [94].
The characterization of Stat6 as a PR coregulator mol-
ecule involved in the antiproliferative and differentiation
effects of progesterone in breast tissue could potentially
explain the biological effects of different progestins on
breast cancer and guide the future discovery of drugs. In
fact, selective progesterone receptor modulators indu-
cing Stat6 cofactor recruitment to PR could prevent
breast cancer development when used in HRT, contra-
ceptives, or treatment of uterine diseases. Further studies
are thus warranted to evaluate the putative tissue-
specific roles of Stat6 in progesterone pathways.
Conclusions
In vitro studies have demonstrated a biphasic progester-
one response, consisting of an initial proliferative burst
followed by a sustained growth arrest. Our present study
demonstrates that Stat6 induces p21 and p27 gene ex-
pression by synergizing with progesterone-bound PR at
the proximal Sp1-binding sites in the p21 and p27 gene
promoters. Stat6 knockdown abolished the inhibitory
effects of progesterone on pRB phosphorylation, G1/S
cell cycle progression, cell proliferation and breast cell
differentiation. Taken together, these data identify Stat6
as a coactivator of PR mediating the growth-inhibitory
and differentiation effects of progesterone on breast can-
cer cells.
Additional files
Additional file 1: Figure S1. Western blotting analysis on Stat6-siRNAs
treated T47D cells. Representative experiments have been performed
with Stat6 siRNA-3. Mock and nonsence control (ns) were used as
negative controls.
Additional file 2: Figure S2. Statistic analysis on the quantifications of
the p21 and p27 promoter sequences bound by Stat6 in Figure 2A. *,
P < 0.05. Columns, mean of three experiments; bars, SD.
Additional file 3: Figure S3. Progestrone treatment increased the level
of Stat6 in the complexes immunoprecipitated with anti- PR but not with
anti-p300. T47D cells were treated with (+) or without (−) 50 ngprogestrone for 24 h. Protein extracts were immunoprecipitated with
anti-PR or anti-P300 antibodies. Normal rabbit IgG was used as the
control. The PR-or P300-associated Stat6 in the resultant immune
complexes was analyzed by western blotting using anti-Stat6 antibody
with anti-PR or -P300 antibody as loading controls.
Additional file 4: Figure S4. Statistic analysis on the quantifications of
the band intensity of PR-B immunoprecipitated by Stat6. *, P < 0.05.
Columns, mean of three experiments; bars, SD.
Additional file 5: Figure S5. Stat6 interacts directly with progesterone-
bound PR via its LTKLL in the TAD domain. A. Coimmunoprecipitation
assays. MCF-7 cells were treated with progesterone (30 nM) and RU486
(10 nM) for 12 h, or untreated. Total protein extracts (50 μg) were then
subjected to Western blotting using a PR antibody either after
immunoprecipitation with anti-Stat6 or nonimmune rabbit IgG (negative
control) antibodies (upper panel) or directly for control of the in-cell PR
levels (lower panel). B, flag–Stat6, either wild type or mutated in the
LTKLL (flag-Stat6m) motif, was assayed for interaction with PR as
described above in the presence of progesterone (10 nM).
Additional file 6: Figure S6. The LXXLL motif of Stat6 is required for
Stat6 to transcriptionally modulate p21 and p27. A, The LXXLL motif in
Stat6 is mutated as indicated. B, Transcriptional activity analysis of
wild-type or mutated Stat6 fusion protein in T47D cells. Each construct
containing wild type or mutated Stat6 fusion protein was transiently
transfected along with P21Luc or P27Luc plasmid into cultured cells and
assayed for luciferase activity. Luciferase activity was normalized to
activities of the empty vector of pGL3-luc, expressed as fold difference.
Transfections were done in three individual experiments. Bars, SD. P ≤0.05
was considered significant. C, results of q-RT-PCR analyses of Stat6,
flag-Stat6-m and p21 and p27 confirm the induction of p21 and p27 by
flag-Stat6-WT. Transcriptional activities of p21 and p27 were inhibited by
flag-Stat6-m transfection in T47D cells. Expression levels of selected genes
(X axis) analyzed by q-RT-PCR were quantified. The Y axis represents the
gene expression level normalized to GAPDH for cells transiently
transfected with the indicated plasmids for 24 h. These results represent
at least three RNA samples per experimental condition run in triplicate.
Additional file 7: Figure S7. Overexpression Stat6 abolishes promotion
of T47D cell proliferation by p21 and p27 siRNA. T47D cells treated with
p21 (700 ng) (left panel), p27 (500 ng) (right panel) and Stat6-flag vector
(500 ng) and their parallel controls, were harvested at 1, 2, or 3 days for
measure of DNA content. ns, not significant; *, P < 0.05; **, P < 0.01 versus
control.
Additional file 8: Figure S8. The induction of p21 and p27 observed
after 24 h progesterone treatment was inhibited by actinomycin D but
was not affected by cycloheximide. Synchronized T47D cells were treated
with or without progesterone (30 nM) for 24 h. mRNA levels are analyzed
using quantitative PCR analysis. Cycloheximide (5ug/ml) or actinomycin D
(10ug/ml) was added to the medium 1 h 30 min before the addition of
progesterone or ethanol (vehicle). NS, not significant; *, P < 0.05 versus
control. n = 3. (TIFF 1112 kb)
Additional file 9: Figure S9. Stat6 siRNA did not affect either the
transcriptional up-regulation by progesterone of metallothionein IIA
(left panel) and pepsinogen C (right panel). T47D cells transfected with
control or Stat6 siRNAs (500 ng), were harvested at the indicated times
for RNA and undergone Quantitative RT-PCR analyses on metallothionein
IIA and pepsinogen C mRNA. mRNA levels are expressed relative to levels
in control siRNA-transfected cells harvested at 24 h, arbitrarily set as 1.
*P ≤ 0.05 versus control.
Additional file 10: Figure S10. Lowering of Sp1 levels resulted in a
significant decrease of p21 and p27 mRNA levels in both the absence (A)
and presence of progesterone (B).T47D cells transfected with control or
Sp-1 siRNA (500 ng), were harvested at the indicated times for RNA and
undergone Quantitative RT-PCR analyses on p21 and p27 mRNA. mRNA
levels are expressed relative to levels in vehicle-treated control
siRNA-transfected cells harvested at 24 h, arbitrarily set as 1. *P ≤ 0.05; **,
P < 0.01 versus control.
Additional file 11: Figure S11. Knocking-down of Stat6 did not
modulate the influence of progesterone on the initial proliferative burst
as shown by proliferation assays. T47D cells transfected with control or
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http://www.biomedcentral.com/1471-2407/14/10Stat6 siRNA (500 ng) for indicated time, were harvested and undergone
proliferation analyses.*P ≤ 0.05 versus control.
Additional file 12: Figure S12. Cell cycle modulators which participate
in G1/S cell cycle progression were not affected by Stat6 siRNA
transfection after progesterone treatment. After 12 h of progesterone
pretreatment T47D cell were transfected with Scrambled siRNA/Stat6
siRNA for 24 h followed by western blotting analysis. Protein profile
analysis was conducted over a time course.
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